This Protein Inhibitors market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.
The protein inhibitors market size has grown strongly in recent years. It will grow from $80.99 billion in 2024 to $88.74 billion in 2025 at a compound annual growth rate (CAGR) of 9.6%. The growth in the historic period can be attributed to drug discovery, drug development, cancer treatment, regulatory approvals.
The protein inhibitors market size is expected to see strong growth in the next few years. It will grow to $125.26 billion in 2029 at a compound annual growth rate (CAGR) of 9%. The growth in the forecast period can be attributed to precision medicine, immunotherapy, drug combinations, aging population. Major trends in the forecast period include data sharing and collaboration, sustainability and ESG, personalized medicine, and adaptive clinical trials.
The rising incidence of chronic diseases is expected to drive the growth of the protein inhibitors market during the forecast period. Conditions such as cancer, cardiovascular diseases, and autoimmune disorders are becoming increasingly common. For example, in June 2024, the National Health Service, a publicly funded healthcare system in England, reported that there were 3,615,330 individuals registered with a general practitioner who had non-diabetic hyperglycemia, or pre-diabetes, in 2023. This represents a significant increase from 3,065,825 in 2022, amounting to an increase of nearly 18%. Consequently, the growing number of individuals suffering from chronic diseases is likely to enhance the demand for protein inhibitors in the market.
The increasing demand for personalized medicine is anticipated to drive the growth of the protein inhibitors market in the future. Personalized medicine customizes medical treatments based on an individual’s unique genetic composition, resulting in more effective and precise healthcare interventions. Protein inhibitors play a vital role in personalized medicine by targeting specific proteins to address diseases according to a person's genetic profile. For example, in February 2024, the Personalized Medicine Coalition, a professional membership organization based in the US, reported that the FDA approved 16 new personalized treatments for patients with rare diseases in 2023, a significant rise from six in 2022. Of the 35 new molecular entities (NMEs) approved, about 34% or 12 are classified as personalized medicines by the Personalized Medicine Coalition (PMC). Thus, the growing interest in personalized medicine is fueling the expansion of the protein inhibitors market.
Leading companies in the protein inhibitor market are increasingly focusing their investments on strategic initiatives, including partnerships and collaborations, to develop new drugs that align with market demand. These strategic alliances enable companies to broaden their product portfolios and expand their geographical reach. For example, in July 2024, Genentech Inc., a US-based biotechnology firm, entered into a collaboration with Relay Therapeutics to develop protein inhibitors, particularly the SHP2 inhibitor RLY-1971 (also known as migoprotafib or GDC-1971). This partnership started with an initial investment of $75 million in 2021, accompanied by an additional $45 million in milestone payments, bringing the total investment to over $120 million before its conclusion. The collaboration aimed to investigate the therapeutic potential of RLY-1971 in conjunction with Genentech's KRAS G12C inhibitor, GDC-6036, for treating advanced solid tumors, including colorectal cancer.
Key players in the protein inhibitors market are prioritizing the development of tyrosine kinase 2 (TYK2) inhibitors, positioning themselves competitively. TYK2 inhibitors, instrumental in treating specific autoimmune conditions by blocking the TYK2 enzyme involved in immune system responses, are a significant focus. For instance, Bristol-Myers Squibb Company gained FDA approval in September 2022 for Sotyktu (deucravacitinib), an oral medication specifically for adults with moderate-to-severe plaque psoriasis eligible for systemic therapy or phototherapy. Sotyktu stands as the first oral treatment with selective inhibition of TYK2 through allosteric mechanisms, marking a significant advancement in this segment of the market.
In June 2022, Pfizer Inc., a US-based pharmaceutical and biotechnology company, acquired ReViral for $525 million. The acquisition strengthens Pfizer's commitment to creating both medications and vaccines to help fight the respiratory syncytial virus while also expanding its anti-infective portfolio (RSV). ReViral is a UK-based clinical-stage biopharmaceutical company pioneering in the discovery and development of innovative antiviral drugs for disorders brought on by the respiratory syncytial virus.
Protein inhibitors are compounds that disrupt the cellular process involved in creating new proteins. They specifically target the steps in protein synthesis within cells, operating at the level of the ribosome. This is possible due to the distinct structural differences between prokaryotic and eukaryotic ribosomes.
The primary types of protein inhibitors include protein kinase inhibitors, monoclonal antibodies, and other related compounds. Monoclonal antibodies, created in laboratories, mimic or enhance the immune system's attack on unwanted cells, such as cancer cells, effectively acting as substitute antibodies. These protein inhibitors find application in treating conditions like oncology (cancer) and inflammatory diseases. They are distributed through various channels including hospital pharmacies, independent pharmacies, and online pharmacies to reach patients in need of these treatments.
The protein inhibitors market research report is one of a series of new reports that provides protein inhibitors market statistics, including protein inhibitors industry global market size, regional shares, competitors with a protein inhibitors market share, detailed protein inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the protein inhibitors industry. This protein inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
Major companies operating in the protein inhibitors market include Bayer AG, AstraZeneca plc, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Apotex Inc., Novartis International AG, GlaxoSmithKline plc, Pfizer Inc., Boehringer Ingelheim International GmbH, Abbott Laboratories, Amgen Inc., Baxter International Inc., Merck & Co. Inc., Interprotein Corporation, AbbVie Inc., Bristol Myers Squibb Company, Galapagos NV, Priovant Therapeutics Inc., Tempus Labs Inc., ReCode Therapeutics Inc., Satellite Bio Inc., Ambagon Therapeutics Inc., Biogen Inc., Eli Lilly and Company, Gilead Sciences Inc., Johnson & Johnson, Regeneron Pharmaceuticals Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Vertex Pharmaceuticals Inc., Lonza Group AG, Catalent Inc., Thermo Fisher Scientific Inc., Charles River Laboratories International Inc., WuXi AppTec Co. Ltd.
North America was the largest region in the protein inhibitors market in 2024. The regions covered in the protein inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the protein inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
The protein inhibitors market consists of sales of erythromycin, tetracycline, chloramphenicol, and aminoglycosides. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The protein inhibitors market size has grown strongly in recent years. It will grow from $80.99 billion in 2024 to $88.74 billion in 2025 at a compound annual growth rate (CAGR) of 9.6%. The growth in the historic period can be attributed to drug discovery, drug development, cancer treatment, regulatory approvals.
The protein inhibitors market size is expected to see strong growth in the next few years. It will grow to $125.26 billion in 2029 at a compound annual growth rate (CAGR) of 9%. The growth in the forecast period can be attributed to precision medicine, immunotherapy, drug combinations, aging population. Major trends in the forecast period include data sharing and collaboration, sustainability and ESG, personalized medicine, and adaptive clinical trials.
The rising incidence of chronic diseases is expected to drive the growth of the protein inhibitors market during the forecast period. Conditions such as cancer, cardiovascular diseases, and autoimmune disorders are becoming increasingly common. For example, in June 2024, the National Health Service, a publicly funded healthcare system in England, reported that there were 3,615,330 individuals registered with a general practitioner who had non-diabetic hyperglycemia, or pre-diabetes, in 2023. This represents a significant increase from 3,065,825 in 2022, amounting to an increase of nearly 18%. Consequently, the growing number of individuals suffering from chronic diseases is likely to enhance the demand for protein inhibitors in the market.
The increasing demand for personalized medicine is anticipated to drive the growth of the protein inhibitors market in the future. Personalized medicine customizes medical treatments based on an individual’s unique genetic composition, resulting in more effective and precise healthcare interventions. Protein inhibitors play a vital role in personalized medicine by targeting specific proteins to address diseases according to a person's genetic profile. For example, in February 2024, the Personalized Medicine Coalition, a professional membership organization based in the US, reported that the FDA approved 16 new personalized treatments for patients with rare diseases in 2023, a significant rise from six in 2022. Of the 35 new molecular entities (NMEs) approved, about 34% or 12 are classified as personalized medicines by the Personalized Medicine Coalition (PMC). Thus, the growing interest in personalized medicine is fueling the expansion of the protein inhibitors market.
Leading companies in the protein inhibitor market are increasingly focusing their investments on strategic initiatives, including partnerships and collaborations, to develop new drugs that align with market demand. These strategic alliances enable companies to broaden their product portfolios and expand their geographical reach. For example, in July 2024, Genentech Inc., a US-based biotechnology firm, entered into a collaboration with Relay Therapeutics to develop protein inhibitors, particularly the SHP2 inhibitor RLY-1971 (also known as migoprotafib or GDC-1971). This partnership started with an initial investment of $75 million in 2021, accompanied by an additional $45 million in milestone payments, bringing the total investment to over $120 million before its conclusion. The collaboration aimed to investigate the therapeutic potential of RLY-1971 in conjunction with Genentech's KRAS G12C inhibitor, GDC-6036, for treating advanced solid tumors, including colorectal cancer.
Key players in the protein inhibitors market are prioritizing the development of tyrosine kinase 2 (TYK2) inhibitors, positioning themselves competitively. TYK2 inhibitors, instrumental in treating specific autoimmune conditions by blocking the TYK2 enzyme involved in immune system responses, are a significant focus. For instance, Bristol-Myers Squibb Company gained FDA approval in September 2022 for Sotyktu (deucravacitinib), an oral medication specifically for adults with moderate-to-severe plaque psoriasis eligible for systemic therapy or phototherapy. Sotyktu stands as the first oral treatment with selective inhibition of TYK2 through allosteric mechanisms, marking a significant advancement in this segment of the market.
In June 2022, Pfizer Inc., a US-based pharmaceutical and biotechnology company, acquired ReViral for $525 million. The acquisition strengthens Pfizer's commitment to creating both medications and vaccines to help fight the respiratory syncytial virus while also expanding its anti-infective portfolio (RSV). ReViral is a UK-based clinical-stage biopharmaceutical company pioneering in the discovery and development of innovative antiviral drugs for disorders brought on by the respiratory syncytial virus.
Protein inhibitors are compounds that disrupt the cellular process involved in creating new proteins. They specifically target the steps in protein synthesis within cells, operating at the level of the ribosome. This is possible due to the distinct structural differences between prokaryotic and eukaryotic ribosomes.
The primary types of protein inhibitors include protein kinase inhibitors, monoclonal antibodies, and other related compounds. Monoclonal antibodies, created in laboratories, mimic or enhance the immune system's attack on unwanted cells, such as cancer cells, effectively acting as substitute antibodies. These protein inhibitors find application in treating conditions like oncology (cancer) and inflammatory diseases. They are distributed through various channels including hospital pharmacies, independent pharmacies, and online pharmacies to reach patients in need of these treatments.
The protein inhibitors market research report is one of a series of new reports that provides protein inhibitors market statistics, including protein inhibitors industry global market size, regional shares, competitors with a protein inhibitors market share, detailed protein inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the protein inhibitors industry. This protein inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
Major companies operating in the protein inhibitors market include Bayer AG, AstraZeneca plc, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Apotex Inc., Novartis International AG, GlaxoSmithKline plc, Pfizer Inc., Boehringer Ingelheim International GmbH, Abbott Laboratories, Amgen Inc., Baxter International Inc., Merck & Co. Inc., Interprotein Corporation, AbbVie Inc., Bristol Myers Squibb Company, Galapagos NV, Priovant Therapeutics Inc., Tempus Labs Inc., ReCode Therapeutics Inc., Satellite Bio Inc., Ambagon Therapeutics Inc., Biogen Inc., Eli Lilly and Company, Gilead Sciences Inc., Johnson & Johnson, Regeneron Pharmaceuticals Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Vertex Pharmaceuticals Inc., Lonza Group AG, Catalent Inc., Thermo Fisher Scientific Inc., Charles River Laboratories International Inc., WuXi AppTec Co. Ltd.
North America was the largest region in the protein inhibitors market in 2024. The regions covered in the protein inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the protein inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
The protein inhibitors market consists of sales of erythromycin, tetracycline, chloramphenicol, and aminoglycosides. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Protein Inhibitors Market Characteristics3. Protein Inhibitors Market Trends and Strategies4. Protein Inhibitors Market - Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market32. Global Protein Inhibitors Market Competitive Benchmarking and Dashboard33. Key Mergers and Acquisitions in the Protein Inhibitors Market34. Recent Developments in the Protein Inhibitors Market
5. Global Protein Inhibitors Growth Analysis and Strategic Analysis Framework
6. Protein Inhibitors Market Segmentation
7. Protein Inhibitors Market Regional and Country Analysis
8. Asia-Pacific Protein Inhibitors Market
9. China Protein Inhibitors Market
10. India Protein Inhibitors Market
11. Japan Protein Inhibitors Market
12. Australia Protein Inhibitors Market
13. Indonesia Protein Inhibitors Market
14. South Korea Protein Inhibitors Market
15. Western Europe Protein Inhibitors Market
16. UK Protein Inhibitors Market
17. Germany Protein Inhibitors Market
18. France Protein Inhibitors Market
19. Italy Protein Inhibitors Market
20. Spain Protein Inhibitors Market
21. Eastern Europe Protein Inhibitors Market
22. Russia Protein Inhibitors Market
23. North America Protein Inhibitors Market
24. USA Protein Inhibitors Market
25. Canada Protein Inhibitors Market
26. South America Protein Inhibitors Market
27. Brazil Protein Inhibitors Market
28. Middle East Protein Inhibitors Market
29. Africa Protein Inhibitors Market
30. Protein Inhibitors Market Competitive Landscape and Company Profiles
31. Protein Inhibitors Market Other Major and Innovative Companies
35. Protein Inhibitors Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Protein Inhibitors Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on protein inhibitors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for protein inhibitors ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The protein inhibitors market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include: the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Product: Protein Kinase Inhibitors; Monoclonal Antibody; Other Products2) By Application: Oncology; Inflammatory Diseases; Other Applications
3) By Distribution Channel: Hospital Pharmacies; Independent Pharmacies; Online Pharmacies
Subsegments:
1) By Protein Kinase Inhibitors: Selective Kinase Inhibitors; Non-selective Kinase Inhibitors; Small Molecule Kinase Inhibitors; Biologic Kinase Inhibitors2) By Monoclonal Antibodies: Chimeric Monoclonal Antibodies; Humanized Monoclonal Antibodies; Fully Human Monoclonal Antibodies; Conjugated Monoclonal Antibodies
3) By Other Products: Peptide Inhibitors; Protein Degradation Technologies; Small Molecule Inhibitors; Combination Therapy Products
Key Companies Mentioned: Bayer AG; AstraZeneca plc; F. Hoffmann-La Roche Ltd.; Teva Pharmaceutical Industries Ltd.; Apotex Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
The major companies featured in this Protein Inhibitors market report include:- Bayer AG
- AstraZeneca plc
- F. Hoffmann-La Roche Ltd.
- Teva Pharmaceutical Industries Ltd.
- Apotex Inc.
- Novartis International AG
- GlaxoSmithKline plc
- Pfizer Inc.
- Boehringer Ingelheim International GmbH
- Abbott Laboratories
- Amgen Inc.
- Baxter International Inc.
- Merck & Co. Inc.
- Interprotein Corporation
- AbbVie Inc.
- Bristol Myers Squibb Company
- Galapagos NV
- Priovant Therapeutics Inc.
- Tempus Labs Inc.
- ReCode Therapeutics Inc.
- Satellite Bio Inc.
- Ambagon Therapeutics Inc.
- Biogen Inc.
- Eli Lilly and Company
- Gilead Sciences Inc.
- Johnson & Johnson
- Regeneron Pharmaceuticals Inc.
- Sanofi S.A.
- Takeda Pharmaceutical Company Limited
- Vertex Pharmaceuticals Inc.
- Lonza Group AG
- Catalent Inc.
- Thermo Fisher Scientific Inc.
- Charles River Laboratories International Inc.
- WuXi AppTec Co. Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 175 |
| Published | April 2025 |
| Forecast Period | 2025 - 2029 |
| Estimated Market Value ( USD | $ 88.74 Billion |
| Forecasted Market Value ( USD | $ 125.26 Billion |
| Compound Annual Growth Rate | 9.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 36 |
